Form 4: Fate Therapeutics Director Matt Abernethy Granted 110,000 Stock Options

Fate Therapeutics Inc. Director Matt Abernethy was granted 110,000 stock options with an exercise price of $1.32, vesting over three years.

Summary

• Matt Abernethy, a Director of Fate Therapeutics Inc. (FATE), was granted 110,000 stock options.
• The options have an exercise price of $1.32 per share.
• The transaction date for the grant was May 29, 2025.
• The shares subject to this option will vest in 36 equal monthly installments following May 29, 2025.
• All shares will be fully vested and exercisable on May 29, 2028, contingent on Mr. Abernethy's continuous service to the Issuer.
• The expiration date for these stock options is May 28, 2035.
• Following this transaction, Mr. Abernethy directly beneficially owns 110,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as the grant of stock options to a director is a standard practice that aligns management's interests with shareholders, indicating continued commitment. It is not a significant event to drastically alter sentiment.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule over three years encourages continued service and commitment from the director.

Negatives

• The exercise price of $1.32 is relatively low, which could be seen as less challenging for the director to achieve profitability compared to a higher strike price.

Risks

• The vesting of options is subject to the reporting person's continuous service to the Issuer, meaning the options could be forfeited if service ceases before full vesting.

Future Outlook

The stock options granted to Director Matt Abernethy are structured to vest over a three-year period, concluding on May 29, 2028, contingent on his continuous service. This aligns his future compensation with the company's long-term performance.

Management Comments

• The filing was signed by Cindy R. Tahl, as Attorney-in-Fact for Matt Abernethy.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, common practice across various industries, including biotechnology, to incentivize leadership and align their financial interests with shareholder value creation.

Related Party Transactions

• The grant of stock options to Matt Abernethy, a Director of Fate Therapeutics Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholder value, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will vest in 36 equal monthly installments following May 29, 2025.
• The options will become fully vested and exercisable on May 29, 2028, assuming continuous service.

Key Dates

Recommendation

Keywords

Fate Therapeutics, FATE, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting Schedule, Matt Abernethy